You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

COLY-MYCIN M Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Coly-mycin M patents expire, and what generic alternatives are available?

Coly-mycin M is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in COLY-MYCIN M is colistimethate sodium. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the colistimethate sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Coly-mycin M

A generic version of COLY-MYCIN M was approved as colistimethate sodium by ADRASTEA PHARMA on February 26th, 1999.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for COLY-MYCIN M?
  • What are the global sales for COLY-MYCIN M?
  • What is Average Wholesale Price for COLY-MYCIN M?
Summary for COLY-MYCIN M
Drug patent expirations by year for COLY-MYCIN M
Pharmacology for COLY-MYCIN M

US Patents and Regulatory Information for COLY-MYCIN M

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations COLY-MYCIN M colistimethate sodium INJECTABLE;INJECTION 050108-002 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for COLY-MYCIN M

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva B.V. Colobreathe colistimethate sodium EMEA/H/C/001225
Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged six years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorised no no no 2012-02-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.